Clinical evaluation in 112 psychiatric patients of a butyrophenone neuroleptic, dehydrobenzperidol (R 4749). A controlled study in 45 patients of dehydrobenzperidol versus haloperidol.
D000328:Adult; D001247:Asthenia / Q000139:chemically induced; D001544:Benperidol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002389:Catatonia / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003863:Depression / Q000188:drug therapy*; D006220:Haloperidol / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D010259:Paranoid Disorders / Q000188:drug therapy*; D011569:Psychiatric Status Rating Scales; D011600:Psychopharmacology; D012466:Salivary Gland Diseases / Q000139:chemically induced; D012559:Schizophrenia / Q000188:drug therapy*; D013610:Tachycardia / Q000139:chemically induced; D014202:Tremor / Q000139:chemically induced; D014786:Vision Disorders / Q000139:chemically induced
D001544:Benperidol; D006220:Haloperidol